紫杉醇注射液联合顺铂注射液治疗晚期卵巢癌的疗效及安全性

Efficacy and safety of paclitaxel combined with cisplatin in the treatment of advanced ovarian cancer

目的探讨分析紫杉醇注射液联合顺铂注射液对晚期卵巢癌的的治疗效果以及对安全性的影响。方法选择2014年1月~2018年6月在开封市妇产医院接受治疗的120例晚期卵巢癌患者作为研究对象,按照治疗方法不同分为对照组和观察组,每组各60例。对照组采给予顺铂注射液进行治疗,观察组给予紫杉醇注射液联合顺铂注射液联合治疗,比较两组患者的疗效、远期疗效以及不良反应发生情况等。结果观察组患者的治疗有效率为76.7%,显著高于对照组的53.3%;观察组疾病控制率为91.7%,显著高于对照组的78.3%(P<0.05)。观察组患者无进展生存期为(24.54±4.78)个月,显著高于对照组的(18.37±4.12)个月;观察组1年、2年与3年生存率显著高于对照组(P<0.05)。在治疗过程中,观察组中有28例患者发生不良反应,不良反应发生率为46.7%,对照组患者不良反应发生率为65.0%。观察组不良反应发生率显著低于对照组(P<0.05)。结论紫杉醇注射液联合顺铂注射液治疗晚期卵巢癌的效果较为理想,具有较好的疗效,可以显著改善患者生存期,同时是一种较为安全的治疗方式,具有一定的临床推广价值。

Objective To evaluate the therapeutic effect of paclitaxel combined with cisplatin injection on advanced ovariancancer and its effect on safety.Methods A total of 120 patients with advanced ovarian cancer who were treated in Kaifeng Maternity Hospital from January 2014 to June 2018,were enrolled in the study.They were divided into control group and observation group according to different treatment methods,with 60 cases in each group.The control group was treated with cisplatin injection.The observation group was treated with paclitaxel injection combined with cisplatin injection.The efficacy,longterm efficacy and adverse reactions of the two groups were compared.Results The effective rate of the observation group was 76.7%, which was significantly higher than that of the control group(53.3%).The disease control rate of the observation group was 91.7%,which was significantly higher than that of the control group(78.3%)(P<0.05).The progression-free survival of the observation group was(24.54±4.78) months,which was significantly higher than that of the control group(18.37±4.12) months.The 1-,2-,and 3-year survival rates of the observation group were significantly higher than those of the control group(P<0.05).During the treatment,28 patients in the observation group had adverse reactions, the incidence of adverse reactions was 46.7%,and the incidence of adverse reactions in the control group was 65.0%. The incidence of adverse reactions in the observation group was significantly lower than that in the control groupt(P<0.05).Conclusion Paclitaxel combined with cisplatin injection is effective in the treatment of advanced ovarian cancer. It has a good curative effect and cansignificantly improve the survival of patients. It is also a safer treatment method and has certain clinical promotion value.